Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1
Launched by OSLO UNIVERSITY HOSPITAL · Aug 13, 2021
Trial Information
Current as of April 28, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how myotonic dystrophy type 1 (DM1), a condition that causes muscle weakness and stiffness, affects the use of arms and hands. The researchers want to find out which tests and surveys can best measure how well people with DM1 can use their upper limbs. By gathering information from patients, the study aims to improve the understanding of upper limb function in DM1, which can help guide future treatments and care.
To participate in this study, individuals need to have a confirmed genetic diagnosis of myotonic dystrophy type 1. The trial is open to all genders, and participants should be between the ages of 65 and 74. Those who cannot understand the questionnaires or perform the functional tests due to language difficulties or cognitive issues may not be eligible. If you join the trial, you'll be asked to complete some surveys and tests related to your arm and hand function, helping researchers learn more about this condition and how to support others living with it.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Genetically confirmed Myotonic Dystrophy type 1
- Exclusion Criteria:
- • Unable to answer or understand questionnaires due to language barriers or cognitive status
- • Unable to perform functional tests
About Oslo University Hospital
Oslo University Hospital is a leading academic medical center in Norway, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes the development of new therapies and treatment strategies. With a multidisciplinary approach, Oslo University Hospital collaborates with various stakeholders, including researchers, healthcare professionals, and industry partners, to enhance clinical outcomes and contribute to the global medical community. Its dedication to ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and respect for participant welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergen, , Norway
Bergen, , Norway
Oslo, , Norway
Siggerud, , Norway
Patients applied
Trial Officials
Kristin L Ørstavik, PHD
Principal Investigator
Oslo University Hospital
Hilde S Robinson, PHD
Study Director
University of Oslo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials